Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.02.19

Dean Edney

Accomplished scientific leader and GSK veteran, Dean Edney joins Sai Life Sciences

Sai Life Sciences, today announced the appointment of Dr. Dean Edney as Senior Vice President and Global Head of Process Research & Development. An accomplished scientific leader and industry veteran with over 25 years of experience in small molecule pharmaceutical process and product development, Dean Edney will split his time between the company’s R&D centre in Hyderabad, India and the new R&D facility in Alderley Park, Manchester, UK.

Making the announcement, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “We are delighted to welcome Dean on board Sai Life Sciences as we open our new Process R&D facility in Manchester, UK. His joining strengthens our vision of creating a world-class, global process R&D organization that applies cutting edge scientific approaches and technology to rapidly deliver high-quality scientific output irrespective of the geographical location.”

As part of its organization-wide transformation initiative, Sai Nxt, the company aspires to enhance its Process Research & Development (PR&D) capability allowing customers to accelerate their research and development programs and deliver commercial products through the rapid application of high quality science to all areas of API process research, development and manufacturing. It will achieve this by combining expertise in rapid, cost effective, process optimisation and scale-up in Hyderabad with expertise in application of new technology and parallel & statistical approaches to process development in Manchester into a single global PR&D organisation.

Commenting on his appointment, Dean Edney said, "I am incredibly excited to be joining Sai Life Sciences at a time of significant investment and growth. My aim is to ensure that the investment in facilities and technology is matched by investment in people and capability, thereby accelerating our clients’ ability to deliver new medicines to patients.”

Previously, over a 25-year career at GlaxoSmithKline, Dean demonstrated a strong track record of cross-functional leadership to deliver projects and develop capability across all phases of API process research & development, from early non-clinical supply and route scouting through to validation of commercial control strategies. Dean received his BSc in Chemistry and Ph.D. in Synthetic Organic Chemistry from the University of Nottingham, UK.

Share article

More News

2026.02.20

Sai Life Sciences to recruit 700+ professionals in FY27

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.The recruitment will span roles […]
Read more

2026.02.06

Sai Life Sciences Limited delivers robust performance in 9MFY26

Revenue up by 43%; EBITDA up by 79%; Net Profit up by 199% Hyderabad, February 05, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the third quarter and nine months ended December 2025. Financial Performance: Particulars […]
Read more

2026.01.28

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform. Under this collaboration, Mabtech and Sai will […]
Read more

2026.01.12

Sai Life Sciences laboratories achieve Green Lab Certification

Sai Life Sciences has achieved Green Lab Certification for two PR&D laboratories and two Medicinal Chemistry laboratories under the My Green Lab (MGL) framework, with a compliance score of over 98%.The certification reflects the company’s systematic efforts to integrate sustainability into daily laboratory operations, with measurable reductions in energy consumption, water usage, waste generation, and […]
Read more

2025.12.19

Sai Life Sciences Releases Sustainability Report 2025

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the release of its Sustainability Report for 2024–25. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition is presented under the […]
Read more